INT109329

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2003
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 6.88
Pain Relevance 0.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (FLT3)
Anatomy Link Frequency
stroma 1
FLT3 (Homo sapiens)
Pain Link Frequency Relevance Heat
nud 1 82.00 Quite High
antagonist 3 73.64 Quite High
headache 4 73.20 Quite High
Pain 21 67.04 Quite High
metalloproteinase 4 60.44 Quite High
palliative 10 25.00 Low Low
imagery 11 5.00 Very Low Very Low Very Low
dexamethasone 11 5.00 Very Low Very Low Very Low
Inflammation 7 5.00 Very Low Very Low Very Low
cytokine 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Recurrence 10 98.76 Very High Very High Very High
Leukemia 34 97.38 Very High Very High Very High
Myeloid Leukemia 45 97.20 Very High Very High Very High
Cancer 308 97.12 Very High Very High Very High
Hyperplasia 2 94.88 High High
Thyroid Disease 2 94.20 High High
Hematologic Neoplasms 15 93.56 High High
Myelodysplastic Syndromes 18 92.88 High High
Gastrointestinal Stromal Tumor 2 91.52 High High
Fibromyalgia 3 91.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
SU5416 (Semaxinib) is a small molecule inhibitor of VEGFR-1 and 2, c-kit and Flt3 [70-72].
Negative_regulation (inhibitor) of Flt3
1) Confidence 0.29 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.84 Pain Relevance 0.17
Inhibition of FLT3 signaling with CEP701 reduces the tumorigenicity of xenografts [80], and CEP 701 has reached phase 2 clinical trials [81].
Negative_regulation (Inhibition) of FLT3
2) Confidence 0.18 Published 2011 Journal Journal of Oncology Section Body Doc Link PMC2958340 Disease Relevance 1.06 Pain Relevance 0
SU11248 (sunitinib malate) is an inhibitor of receptor tyrosine kinases for VEGFR1, VEGFR2, PDGFR, c-kit, and Flt-3.
Negative_regulation (inhibitor) of Flt-3
3) Confidence 0.16 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.70 Pain Relevance 0.03
The Cancer and Leukemia Group B (CALGB) 8030, a phase III, trial showed disappointing results for OS and was terminated early.96 Sorafenib, a multikinase inhibitor against VEGFR, platelet-derived growth factor receptor, Kit, and Flt-3, was demonstrated to have no activity in combination with gemcitabine in phase II trial,97 although it is being investigated in the second-line setting.98

Secreted protein acid rich in cysteine (SPARC): the stroma as the target

Negative_regulation (inhibitor) of Flt-3 in stroma associated with leukemia and cancer
4) Confidence 0.12 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2939765 Disease Relevance 0.83 Pain Relevance 0
SU5416 is a small molecule RTK inhibitor (RTKI) of VEGFR-2, c-kit, and both wild-type and mutant FLT3.
Negative_regulation (inhibitor) of mutant FLT3
5) Confidence 0.08 Published 2003 Journal Blood Section Abstract Doc Link 12649163 Disease Relevance 1.20 Pain Relevance 0.14
Developmental therapeutics in AML include drug resistance modulation, anti-angiogenic strategies, immunotherapy, and signal transduction-active agents, particularly the farnesyl transferase inhibitors as well as those molecules that inhibit the FLT3 tyrosine kinase, activated via mutation in 30% of patients.
Negative_regulation (inhibit) of FLT3 tyrosine kinase associated with myeloid leukemia
6) Confidence 0.08 Published 2004 Journal Hematology Am Soc Hematol Educ Program Section Abstract Doc Link 15561679 Disease Relevance 0.70 Pain Relevance 0
The molecule also inhibits other tyrosine kinase receptors including VEGFR1, VEGFR2, VEGFR3, PDGFRB, flt-3, and c-kit.
Negative_regulation (inhibits) of flt-3
7) Confidence 0.07 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2804796 Disease Relevance 1.54 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox